Ãëàâíàÿ    Ex Libris    Êíèãè    Æóðíàëû    Ñòàòüè    Ñåðèè    Êàòàëîã    Wanted    Çàãðóçêà    ÕóäËèò    Ñïðàâêà    Ïîèñê ïî èíäåêñàì    Ïîèñê    Ôîðóì   
blank
Àâòîðèçàöèÿ

       
blank
Ïîèñê ïî óêàçàòåëÿì

blank
blank
blank
Êðàñîòà
blank
Gomperts B.D., Tatham P.E.R., Kramer I.M. — Signal Transduction
Gomperts B.D., Tatham P.E.R., Kramer I.M. — Signal Transduction



Îáñóäèòå êíèãó íà íàó÷íîì ôîðóìå



Íàøëè îïå÷àòêó?
Âûäåëèòå åå ìûøêîé è íàæìèòå Ctrl+Enter


Íàçâàíèå: Signal Transduction

Àâòîðû: Gomperts B.D., Tatham P.E.R., Kramer I.M.

Àííîòàöèÿ:

Signal Transduction is a text reference on cellular signalling processes. Starting with the basics, it explains how cells respond to external cues (hormones, cytokines, neurotransmitters, adhesion molecules, extracellular matrix, etc), and shows how these inputs are integrated and co-ordinated. The first half of the book provides the conceptual framework, explaining the formation and action of second messengers, particulary cyclic nucleotides and calcium, and the mediation of signal pathways by GTP-binding proteins. The remaining chapters deal with the formation of complex signalling cascades employed by cytokines and adhesion molecules, starting at the membrane and ending in the nucleus, there to regulate gene transcription. In this context, growth is an important potential outcome and this has relevance to the cellular transformations that underlie cancer. The book ends with a description at the molecular level of how signalling proteins interact with their environment and with each other through their structural domains. Each main topic is introduced with a historical essay, detailing the sources key observations and experiments that set the scence for recent and current work.


ßçûê: en

Ðóáðèêà: Òåõíîëîãèÿ/

Ñòàòóñ ïðåäìåòíîãî óêàçàòåëÿ: Ãîòîâ óêàçàòåëü ñ íîìåðàìè ñòðàíèö

ed2k: ed2k stats

Ãîä èçäàíèÿ: 2002

Êîëè÷åñòâî ñòðàíèö: 424

Äîáàâëåíà â êàòàëîã: 21.12.2005

Îïåðàöèè: Ïîëîæèòü íà ïîëêó | Ñêîïèðîâàòü ññûëêó äëÿ ôîðóìà | Ñêîïèðîâàòü ID
blank
Ïðåäìåòíûé óêàçàòåëü
Hormones, receptor binding      25—26
HsEg5      238
Human immunodeficiency virus      see “HIV”
Hyaluronan      324
ICAD (inhibitor of capsase activated DNAase)      336
ICAM (intercellular adhesion molecule)      285 318 319 349 351
ICAM-1      352
ICRAC      158 161
IgE-R (IgE high affinity receptor)      183
IgE-R, signalling pathways      288—289 289
IGF1 (insulin-like growth factor 1)      see “Somatomedin 1”
IGF2 (insulin-like growth factor 2)      see “Somatomedin 2”
IL-2 (interleukin-2)      213 285 288
IL-2 (interleukin-2) receptor      283
IL-3 (interleukin-3)      249
IL-6 (interleukin-6)      288 349
IL-8 (interleukin-8)      349
Immunoglobulin receptors      161 283
Immunoglobulin superfamily      318—319 378
Immunophilins      154 388 389
Immunoreceptor tyrosine-based activation motifs      see “ITAMs”
InaC      207 208
InaD      207 208
Inflammation      23 345—349 346 347
Inflammation, eicosanoid actions      23
Inflammation, PKC      212—217
Inflammatory mediators      345 347 348
Inhibitor of capsase activated DNAase      see “ICAD”
INK4 (inhibitor of cyclin-dependent kinase-4)      240 241 242
Inositol lipid cycle      179 180
Inositol-1, 4, 5-triphosphate      see “IP3”
Insulin      3 19 20 22 299 310
Insulin receptor      4
Insulin receptor substrates      see “IRS”
Insulin receptor, activation      259 262
Insulin receptor, PI 3-kinase activation      306 306
Insulin receptor, signalling      299—300
Insulin stimulated protein kinase      see “ISPK”
Insulin, adenylyl cyclase activation      61
Insulin, glucose transport activation      307—308
Insulin, glycogen synthase activation      306—307 308
Insulin, insulin receptor interaction      28 306
Insulin, PKB activation      307
Insulin-derived growth factor      see “IGF”
Insulin-like growth factor 1 (IGFl)      see “Somatomedin 1”
Insulin-like growth factor 2 (IGF2)      see “Somatomedin 2”
Insulin-stimulated protein kinase      see “ISPK”
Integrins      249 317 318 319—320 319 320 325 328 329
Integrins, leukocyte trafficking      351 352—353
Intercellular adhesion molecule      see “ICAM”
Interferon$\alpha$-receptor      see “$INF\alpha$-receptor”
Interferons      23 290—291
Interleukin-2      see “IL-2”
Interleukin-3      see “IL-3”
Interleukin-6      see “IL-6”
Interleukin-8      see “IL-8”
Interleukins      23
Intermediate filaments      331
Interphase      233
Intracellular (second) messengers      25
Inverse agonists      59 60 60 61 76 77
Ion channel-linked receptors      42—51
Ion channels, cyclic AMP regulation      197
Ion channels, cytosolic $Ca^{2+}$ elevation      153
Ion channels, patch clamp studies      44—46 45
Ion channels, site-specific blocking      48
Ionomycin      150
IP3 (inositol-1, 4, 5-triphosphate)      25 120 122 216 261 265 285
IP3 receptor      154 155 756
IP3 receptor, calcium channel regulation      156 159 166 167 167 184
IP3 receptor, isoforms      155 156
IP3, intracellular $Ca^{2+}$ mobilization      154—157 167
IRA (GTPase activating G-protein)      108
IRS (insulin receptor substrates)      306
IRS-1      306
Isoprenaline (isoproterenol)      35—36 37 62
ISPK (insulin stimulated protein kinase)      385
ITAMs (immunoreceptor tyrosine-based activation motifs)      286
JAK2 (Janus-kinase-2)      293 294 380—381
JNK (Jun N-terminal kinase)      210 272 274
JNK, apoptosis induction      327—328 328
JNK-1 (Jun N-terminal kinase-1)      209
Jun      208 209 265 271 272
Keratin      331—332
Kinases      25
Kinetochore      238 244 245
KIP/CIP      240 241—242
L-selectin      323 354
L-type $Ca^{2+}$ channels      157
Lambda-PKC interaction protein      see “LIP”
Lamin      238 337
Large T-antigen      243 250 251
LAT (linker for activation of T-cells)      287 290
LC20      238
Lck      285 286 376 377
Let-60      268
Leucine zipper      208
Leukaemia      225—226 226 293
Leukocyte common antigen      see “CD45”
Leukocytes, adhesion/extravasion      345 352—353 354 354 355
Leukocytes, inflammatory response      212 345
Leukocytes, protection from apoptosis      326
Leukocytes, trafficking      345—355
Leukotriene LTB4      288
Leukotrienes      23
LFA-1 (lymphocyte function-associated antigen-1)      285 317 318
LH (luteinizing hormone)      20
LH receptors      194
Ligands, extracellular first messengers      19 20
Ligands, receptor interactions      14—16
Ligands, receptor interactions, binding      25—29
Linker for activation of T-cells      see “LAT”
LIP (lambda-PKC interaction protein)      205
Lipid microdomains      290
LPA (lysophosphatidic acid)      204 205
LSD (lysergic acid diethylamide)      14
Luteinizing hormone      see “LH”
Lymphocyte function-associated antigen-1      see “LFA-1”
Lymphotoxin      349
lyn      288 294
Lysergic acid diethylamide      see “LSD”
Lysophosphatidic acid      see “LPA”
M phase      233 see
M phase, checkpoint      234 244—245
Mac-1      215 316 318
MAD      365
Mad1      244
Mad2      244
MadCAM      319
Major histocompatibility complex      see “MHC”
MAP kinase (mitogen activated protein kinase)      209 210 270—271 270
MAP kinase phosphatase-1      see “MKP-1”
MAP kinase, negative regulation      379—380 380
MAP kinase-ERK kinase      see “MEK”
MAP kinase-integrating kinase-1      see “Mnkl”
MAP kinase-related proteins      273—275 274 275
MARCKS      200
Mast cells      23 158 212 288 289
Mastoparan      289
MEK (MAP kinase-ERK kinase)      271
MEK1      407
MEKK      350
Melanin      132
Metabotropic receptors      42 56—57
Metastasis      249 322
Metoprolol      36 37
MH1      365 370
MH2      365 370
MHC (Major histocompatibility complex)      283 285
Microfilaments      180
Middle T-antigen      257
Mitogen activated protein kinase      see “MAP kinase”
Mitosis      233 238—240 239 see
MKP-1 (MAP kinase phosphatase-1)      379—380 380
MLCK (myosin light chain kinase)      184 275
Mnkl (MAP kinase-integrating kinase-1)      272 273
Monoclonal antibodies      316—317
Muscarine      39 40 41
Muscarinic receptors      39 40 42
Muscarinic receptors, acetylcholine interaction      40 55
Muscarinic receptors, antagonists      40 41
Muscarinic receptors, G-protein signalling      42 51 83—84
Muscarinic receptors, subtypes      40 41
Myc      271
myosin      182
Myosin II light chain      see “LC20”
Myosin light chain kinase      see “MLCK”
Mytl kinase      237 238
N-Ras      86
NAADP (nicotinic acid adenine dinucleotide Phosphate)      159 160—161 160
NADPH oxidase, respiratory burst      214—215 215 216
NCAM (neuronal cell adhesion molecule)      316 317 318 319
Nerve growth factor      see “NGF”
Neurite outgrowth      315
Neurofibromatosis type 1      94
Neurofibromin      94 95
Neuromodulators      19
Neuromuscular junction, acetylcholine actions      38 40
Neuromuscular junction, nicotinic receptors      40 42—43 43
Neuromuscular junction, nicotinic receptors, subunits      44 45
Neuronal cell adhesion molecule      see “NCAM”
Neuropeptides      24
Neurotransmitters      10—12 21 24
Neurotransmitters, $Ca^{2+}$ signalling      181—182
Neurotransmitters, mutiple effects      19
Neutral antagonists      60
Neutrophils, antimicrobial defences      213 214
Neutrophils, antimicrobial defences, respiratory burst      213—215 275
Neutrophils, inflammatory response      213
NF-$\kappa B$ (nuclear factor $\kappa B$)      349 350 351
NF-AT      287 288 309 388 390
NFI      94
NGF (nerve growth factor)      227-230
Nicotine      15 16 39 41
Nicotinic acid adenine dinucleotide phosphate      see “NAADP”
Nicotinic receptors      39 40
Nicotinic receptors, $\alpha$-bungarotoxin-mediated inactivation      43—44
Nicotinic receptors, acetylcholine interactions      38 49
Nicotinic receptors, antagonists      40 41
Nicotinic receptors, desensitization      49—50
Nicotinic receptors, electron microscopy      49 50
Nicotinic receptors, ion channel function      42—50
Nicotinic receptors, patch clamp studies      44—46 45
Nicotinic receptors, sarcolemma      182
Nicotinic receptors, subunits      44—45 45 51
Nicotinic receptors, subunits, membrane spanning sequences      47—49 48 49
Nicotinic receptors, subunits, sequence homologies      44—45 46 47
Nifedipine      157
NIK      350
Nitric oxide      see “NO”
Nitric oxide synthase      see “NOS”
NLS (nuclear localization sequence)      388
NMDA, glutamate receptor activation      158
NO (nitric oxide)      177 178
Non-receptor protein tyrosine kinase family      283-284 284 294 294
Noradrenaline (norepinephrine)      9 10 19 20 22 33 34
Noradrenaline, adenylyl cyclase activation      63
NOS (nitric oxide synthase)      177—178 309
Nuclear factor $\kappa B$      see “NF-$\kappa B$
Nuclear localization sequence      see “NLS”
Nucleolin      238
nucleotides      71
Occludin      331
Odorant substances, receptor interactions      54 197
Oestradiol      2
Okadaic acid      190 195 384
Olfactory cell ion channels      197
Oncogenes      208 292—294
Oncogenes, non-viral      293—294
Oncogenes, tyrosine kinase signal transduction components      293
Oncogenes, viral      292—293
Opiate receptors      99
Opiate receptors, homodimers      62
Opsin      61 127 139
Opsonization      215
Organophosphorus compounds      39 58
Organotherapy      5—8
Osteopontin      317
Oxytocin      20 24
Oxytocin receptor, progesterone actions      61 76
P-glycoproteins      112
P-selectin      323 351 354
P107      235 236
P130      235
P21-activated protein kinase      see “PAK”
P38/HOG pathway      274
p53      242—243 249 250
P70 S6-kinase      307
PAK (p21-activated protein kinase)      337
PAR receptors (proteinase activated receptors)      58
Paracrine agents      19
Parathyroid $Ca^{2+}$-sensing receptors      56
Parathyroid hormone      see “PTH”
Partial agonists      59
Patch clamp studies      42 44—46 45
PCNA (proliferating cell nuclear antigen)      241
PDGF (platelet derived growth factor)      22 249
PDGF receptor, activation      259 261 262 265 271
PDGF, historical aspects      230—231
PDGF, protein kinase B activation      307
PDKI (3-phosphoinositide dependent protein kinase-1)      305 310
Pdsl      238 245
PECAM      319
Pertussis toxin      80 116—119 118 197
PH (pleckstrin homology) domains      398—399 400 401
Phagocytosis      213 215
Phentolamine      63
Phenylephrine      36 37
Pheromone-induced mating response      96—100
Phorbol esters      199 201
Phorbol esters, inflammatory activity      212—215 213
Phorbol esters, tumour promoting activity      208
Phorbol myristate acetate      see “PMA”
Phosphatases      25 175
Phosphatidylinositol      see “PI”
Phosphatidylinositol 3-kinase      see “PI 3-kinase”
Phosphatidylinositol 4, 5-bisphosphate      see “PI(4 5)P2”
Phosphodiesterase, $Ca^{2+}$-calmodulin-sensitive      176—177
Phospholipase A2      see “PLA2”
Phospholipase C      see “PLC”
Phospholipase D      see “PLD”
Phospholipases      120—121 120
Phosphorylase      189 190 191 192 387
Phosphorylase kinase      175 191 275 386
Phosphorylation reactions      25 31 189—217
Phosphorylation reactions, $p67^{phox}$ byPKC      215—217
Phosphorylation reactions, adenylyl cyclase regulation      115 191
Phosphorylation reactions, cyclic AMP signal amplification      191—192
Phosphorylation reactions, glycogenosis      175
Phosphorylation reactions, protein kinase activity regulation      407 407
Phosphorylation reactions, protein kinase activity regulation, PKC      200 202 203
Phosphorylation reactions, receptor downregulation      49 50 84 85 85
Photoreceptors, cells      130—135
Photoreceptors, dark current      133 134
Photoreceptors, development in Drosophila      266—268 267 268
Photoreceptors, function      130—135
Photoreceptors, function, signal amplification      133
Photoreceptors, sensitivity      127—128 129
Phototransduction      see “Visual transduction”
PI (phosphatidylinositol)      119 120 122 301
1 2 3 4 5
blank
Ðåêëàìà
blank
blank
HR
@Mail.ru
       © Ýëåêòðîííàÿ áèáëèîòåêà ïîïå÷èòåëüñêîãî ñîâåòà ìåõìàòà ÌÃÓ, 2004-2024
Ýëåêòðîííàÿ áèáëèîòåêà ìåõìàòà ÌÃÓ | Valid HTML 4.01! | Valid CSS! Î ïðîåêòå